Urinary Tract Infections (UTI)

Menopausal Hormonal Therapy May Cut UTI Risk

Publish Date July 23, 2020

New study is the first focused analysis of bacterial diversity in the urogenital tract of postmenopausal women, according to investigators.

Shorter Antibiotic Treatment Duration Effective for Acute Uncomplicated Cystitis

Publish Date July 1, 2020

A team of investigators conducted a systematic review and meta-analysis to assess whether a shorter-than-recommended duration of antibiotic treatment can be effective for the management of acute uncomplicated cystitis.

Trial Comparing Sulopenem to Ertapenem for cUTI Misses End Point

Publish Date June 5, 2020

Findings showed that the trial failed to demonstrate noninferiority, with a responder rate of 67.8% for sulopenem at the test of cure visit compared with 73.9% for ertapenem (difference of -6.1%; [95% CI, -12.0, -0.1])

Novel Antibiotic Combo Beats Piperacillin-Tazobactam in Complicated UTI Trial

Publish Date March 3, 2020

The combination of cefepime, a cephalosporin antibiotic, and enmetazobactam, a novel extended-spectrum β-lactamase inhibitor (Exblifep; Allecra Therapeutics) was found to be superior to piperacillin-tazobactam in the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis, according to top-line results from the phase 3 ALLIUM trial. The double-blind, non-inferiority study included 1034 patients randomized to…

Cleansing Agent for Reducing Recurrent UTI Risk Now Available OTC

Publish Date March 3, 2020

Theraworx® Protect U-Pak (Avadim Health), a hygiene solution developed to address risk factors associated with recurrent urinary tract infections (UTIs), is now available in retail pharmacies.

UTI Recurrence in Pediatric Patients: Antibiotic Treatment Duration Examined

Publish Date March 2, 2020

Several factors were associated with an increased risk of UTI recurrence. These included antibiotic exposure prior to treatment, pyelonephritis on diagnosis date, having a follow-up visit during antibiotic treatment, receiving parenteral antibiotics.

Fetroja Now Available for Treatment of Complicated UTI

Publish Date February 26, 2020

Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

Vegetarian Diet Tied to Lower Risk for Urinary Tract Infection

Publish Date February 6, 2020

Protective association mainly seen in women, in never smokers, and for uncomplicated UTI.

Routine Blood Tests Not Warranted for Vesicoureteral Reflux Prophylaxis

Publish Date January 6, 2020

Trimethoprim-sulfamethoxazole prophylaxis for vesicoureteral reflux in young children has no adverse effect on complete blood count, serum electrolytes, or creatinine, a study found.

Fetroja Approved for Complicated UTI in Patients With Limited or No Alternative Tx Options

Publish Date November 21, 2019

The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…